Sanofi Competitors

Johnson & Johnson (NYSE:JNJ) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Sanofi has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Johnson & Johnson has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Johnson & Johnson and Sanofi, as reported by MarketBeat.

Johnson & Johnson presently has a consensus price target of $182.6154, indicating a potential upside of 12.56%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities research analysts clearly believe Johnson & Johnson is more favorable than Sanofi.

Valuation & Earnings

This table compares Johnson & Johnson and Sanofi's revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Johnson & Johnson and Sanofi's net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats Sanofi on 15 of the 17 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.4%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 49 consecutive years and Sanofi has increased its dividend for 1 consecutive years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Volatility & Risk

Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Sanofi, as reported by MarketBeat.com.

Abbott Laboratories currently has a consensus price target of $123.2222, indicating a potential downside of 0.91%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Sanofi.

Valuation and Earnings

This table compares Abbott Laboratories and Sanofi's top-line revenue, earnings per share and valuation.

Abbott Laboratories has higher earnings, but lower revenue than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

72.6% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 6.9% of Sanofi shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Abbott Laboratories and Sanofi's net margins, return on equity and return on assets.

Summary

Abbott Laboratories beats Sanofi on 10 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Institutional and Insider Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 6.9% of Sanofi shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Pfizer has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Pfizer and Sanofi's net margins, return on equity and return on assets.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.0%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Sanofi has increased its dividend for 1 consecutive years.

Valuation and Earnings

This table compares Pfizer and Sanofi's top-line revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Sanofi. Pfizer is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Pfizer and Sanofi, as reported by MarketBeat.com.

Pfizer currently has a consensus price target of $38.5714, indicating a potential upside of 0.00%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Sanofi.

Summary

Pfizer beats Sanofi on 10 of the 16 factors compared between the two stocks.

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

9.9% of Novartis shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Novartis has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Profitability

This table compares Novartis and Sanofi's net margins, return on equity and return on assets.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Novartis pays out 39.7% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Sanofi has increased its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Novartis and Sanofi's gross revenue, earnings per share and valuation.

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Novartis and Sanofi, as reported by MarketBeat.com.

Novartis currently has a consensus price target of $108.50, indicating a potential upside of 23.27%. Given Novartis' higher possible upside, equities analysts plainly believe Novartis is more favorable than Sanofi.

Summary

Novartis beats Sanofi on 11 of the 15 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Profitability

This table compares Merck & Co., Inc. and Sanofi's net margins, return on equity and return on assets.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Sanofi has increased its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Merck & Co., Inc. and Sanofi's gross revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Sanofi. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Merck & Co., Inc. and Sanofi, as reported by MarketBeat.com.

Merck & Co., Inc. currently has a consensus price target of $96.2727, indicating a potential upside of 24.27%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities analysts plainly believe Merck & Co., Inc. is more favorable than Sanofi.

Summary

Merck & Co., Inc. beats Sanofi on 12 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Profitability

This table compares AbbVie and Sanofi's net margins, return on equity and return on assets.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Sanofi has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation & Earnings

This table compares AbbVie and Sanofi's gross revenue, earnings per share and valuation.

AbbVie has higher earnings, but lower revenue than Sanofi. AbbVie is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for AbbVie and Sanofi, as reported by MarketBeat.com.

AbbVie currently has a consensus price target of $115.75, indicating a potential upside of 7.27%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than Sanofi.

Summary

AbbVie beats Sanofi on 13 of the 17 factors compared between the two stocks.